MARY TULLOS: Open Payments
NPI 1639339682 · SOUTHAVEN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$867 in 45 payments from 17 companies in 2025. Trend: 2023 $1,110 · 2024 $1,021 · 2025 $867
Food & beverage: $867
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $178 |
| Lilly USA, LLC | 10 | $140 |
| Novo Nordisk Inc | 5 | $81 |
| Boston Scientific Corporation | 2 | $69 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| ABBVIE INC. | 2 | $48 |
| Electromed, Inc. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $29 |
Products named: AIRSUPRA, MOUNJARO, Kerendia, REXULTI, CDS - MCT/CEM Monitoring, Ozempic, SMARTVEST, QULIPTA.
Industry payments across MS — which companies pay providers there.
